Improvement in outcomes of clinical islet transplantation: 1999-2010.
2012 Jul
Journal Article
Authors:
Barton, F.B.;
Rickels, M.R.;
Alejandro, R.;
Hering, B.J.;
Wease, S.;
Naziruddin, B.;
Oberholzer, J.;
Odorico, J.S.;
Garfinkel, M.R.;
Levy, M.;
Pattou, F.;
Berney, T.;
Secchi, A.;
Messinger, S.;
Senior, P.A.;
Maffi, P.;
Posselt, A.;
Stock, P.G.;
Kaufman, D.B.;
Luo, X.;
Kandeel, F.;
Cagliero, E.;
Turgeon, N.A.;
Witkowski, P.;
Naji, A.;
O'Connell, P.J.;
Greenbaum, C.;
Kudva, Y.C.;
Brayman, K.L.;
Aull, M.J.;
Larsen, C.;
Kay, T.W.H.;
Fernandez, L.A.;
Vantyghem, M.C.;
Bellin, M.;
Shapiro, A.M.James
Secondary:
Diabetes Care
Volume:
35
Pagination:
1436-45
Issue:
7
PMID:
22723582
Keywords:
Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Glycated Hemoglobin A; Humans; Islets of Langerhans Transplantation; Middle Aged; Registries; Treatment Outcome
Abstract:
OBJECTIVE: To describe trends of primary efficacy and safety outcomes of islet transplantation in type 1 diabetes recipients with severe hypoglycemia from the Collaborative Islet Transplant Registry (CITR) from 1999 to 2010.RESEARCH DESIGN AND METHODS: A total of 677 islet transplant-alone or islet-after-kidney recipients with type 1 diabetes in the CITR were analyzed for five primary efficacy outcomes and overall safety to identify any differences by early (1999-2002), mid (2003-2006), or recent (2007-2010) transplant era based on annual follow-up to 5 years.RESULTS: Insulin independence at 3 years after transplant improved from 27% in the early era (1999-2002, n = 214) to 37% in the mid (2003-2006, n = 255) and to 44% in the most recent era (2007-2010, n = 208; P = 0.006 for years-by-era; P = 0.01 for era alone). C-peptide ≥0.3 ng/mL, indicative of islet graft function, was retained longer in the most recent era (P < 0.001). Reduction of HbA(1c) and resolution of severe hypoglycemia exhibited enduring long-term effects. Fasting blood glucose stabilization also showed improvements in the most recent era. There were also modest reductions in the occurrence of adverse events. The islet reinfusion rate was lower: 48% by 1 year in 2007-2010 vs. 60-65% in 1999-2006 (P < 0.01). Recipients that ever achieved insulin-independence experienced longer duration of islet graft function (P < 0.001).CONCLUSIONS: The CITR shows improvement in primary efficacy and safety outcomes of islet transplantation in recipients who received transplants in 2007-2010 compared with those in 1999-2006, with fewer islet infusions and adverse events per recipient.
